Intervention Review

You have free access to this content

Etanercept for the treatment of rheumatoid arthritis

  1. Anne Lethaby1,†,
  2. Maria Angeles Lopez-Olivo2,‡,
  3. Lara J Maxwell3,
  4. Amanda Burls4,
  5. Peter Tugwell5,6,7,*,
  6. George A Wells8

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 13 JUN 2012

DOI: 10.1002/14651858.CD004525.pub2


How to Cite

Lethaby A, Lopez-Olivo MA, Maxwell LJ, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD004525. DOI: 10.1002/14651858.CD004525.pub2.

Author Information

  1. 1

    University of Auckland, Department of Obstetrics and Gynaecology, Auckland, New Zealand

  2. 2

    The University of Texas, M.D. Anderson Cancer Center, Department of General Internal Medicine, Houston, Texas, USA

  3. 3

    University of Ottawa, Centre for Global Health, Institute of Population Health, Ottawa, Ontario, Canada

  4. 4

    City University London, School of Health Sciences, London, UK

  5. 5

    Faculty of Medicine, University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada

  6. 6

    Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

  7. 7

    University of Ottawa, Institute of Population Health & Department of Epidemiology and Community Medicine, Ottawa, Ontario, Canada

  8. 8

    University of Ottawa, Department of Epidemiology and Community Medicine, Ottawa, Ontario, Canada

  1. Joint first author

  2. Joint first author

*Peter Tugwell, tugwell.bb@uottawa.ca. kerry.obrien@uottawa.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 31 MAY 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 1 ACR50.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 2 ACR70.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 3 Remission (DAS < 2.6).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 4 HAQ (mean improvement from baseline).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 5 Total Sharp Score.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 6 Total withdrawals.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 7 Withdrawals due to adverse events.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 8 Serious adverse events.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to DMARDs), Outcome 9 Serious Infections.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 1 ACR50.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 2 ACR70.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 3 HAQ (mean reduction from baseline).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 4 Total withdrawals.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 5 Withdrawals due to adverse events.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Summary of findings table: etanercept (ET) 25 mg + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD (partial responders to methotrexate (MTX)), Outcome 6 Serious adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 DAS.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Remission (DAS < 1.6).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 5 Remission (DAS < 2.6).
[Analysis 4.6]
Analysis 4.6. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 6 Change in Total Sharp Score (from baseline).
[Analysis 4.7]
Analysis 4.7. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 7 Change in Erosion Score (from baseline).
[Analysis 4.8]
Analysis 4.8. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 4.9]
Analysis 4.9. Comparison 4 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
[Analysis 5.1]
Analysis 5.1. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR70.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR50.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Remission (DAS < 1.6).
[Analysis 5.5]
Analysis 5.5. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 5 Remission (DAS < 2.6).
[Analysis 5.6]
Analysis 5.6. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 6 Change in Total Sharp Score (from baseline).
[Analysis 5.7]
Analysis 5.7. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 7 Change in Erosion Score (from baseline).
[Analysis 5.8]
Analysis 5.8. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 5.9]
Analysis 5.9. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 9 No progression of joint damage.
[Analysis 5.10]
Analysis 5.10. Comparison 5 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 10 DAS 28.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Remission (DAS < 1.6).
[Analysis 6.5]
Analysis 6.5. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 5 Remission (DAS < 2.6).
[Analysis 6.6]
Analysis 6.6. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
[Analysis 6.7]
Analysis 6.7. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 7 Change in Erosion Score (from baseline).
[Analysis 6.8]
Analysis 6.8. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 6.9]
Analysis 6.9. Comparison 6 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
[Analysis 7.1]
Analysis 7.1. Comparison 7 Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 ACR20.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 ACR50.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 ACR70.
[Analysis 7.4]
Analysis 7.4. Comparison 7 Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Change in Total Sharp Score (from baseline).
[Analysis 7.5]
Analysis 7.5. Comparison 7 Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Change in Erosion Score (from baseline).
[Analysis 7.6]
Analysis 7.6. Comparison 7 Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 Change in Joint Space Narrowing Score (from baseline).
[Analysis 7.7]
Analysis 7.7. Comparison 7 Efficacy at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 DAS.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 ACR20.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 ACR50.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 ACR70.
[Analysis 8.4]
Analysis 8.4. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Remission (DAS < 1.6).
[Analysis 8.5]
Analysis 8.5. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Remission (DAS < 2.6).
[Analysis 8.6]
Analysis 8.6. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
[Analysis 8.7]
Analysis 8.7. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 Change in Erosion Score (from baseline).
[Analysis 8.8]
Analysis 8.8. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 8.9]
Analysis 8.9. Comparison 8 Efficacy at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 9 No progression of joint damage (TSS ≤ 0.5).
[Analysis 9.1]
Analysis 9.1. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 ACR20.
[Analysis 9.2]
Analysis 9.2. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 ACR50.
[Analysis 9.3]
Analysis 9.3. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 ACR70.
[Analysis 9.4]
Analysis 9.4. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Remission (DAS < 1.6).
[Analysis 9.5]
Analysis 9.5. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Remission (DAS < 2.6).
[Analysis 9.6]
Analysis 9.6. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 Change in Total Sharp Score (from baseline).
[Analysis 9.7]
Analysis 9.7. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 Change in Erosion Score (from baseline).
[Analysis 9.8]
Analysis 9.8. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 9.9]
Analysis 9.9. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 9 No progression of joint damage.
[Analysis 9.10]
Analysis 9.10. Comparison 9 Efficacy at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 10 DAS 28.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 ACR20.
[Analysis 10.2]
Analysis 10.2. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 ACR50.
[Analysis 10.3]
Analysis 10.3. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 ACR70.
[Analysis 10.4]
Analysis 10.4. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Remission (DAS < 1.6).
[Analysis 10.5]
Analysis 10.5. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Remission (DAS < 2.6).
[Analysis 10.6]
Analysis 10.6. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 Change in Total Sharp Score (from baseline).
[Analysis 10.7]
Analysis 10.7. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 Change in Erosion Score (from baseline).
[Analysis 10.8]
Analysis 10.8. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 10.9]
Analysis 10.9. Comparison 10 Efficacy at three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 9 No progression of joint damage (TSS ≤ 0.5).
[Analysis 11.1]
Analysis 11.1. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
[Analysis 11.2]
Analysis 11.2. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
[Analysis 11.3]
Analysis 11.3. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
[Analysis 11.4]
Analysis 11.4. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 DAS < 3.2.
[Analysis 11.5]
Analysis 11.5. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
[Analysis 11.6]
Analysis 11.6. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 6 EULAR - good response.
[Analysis 11.7]
Analysis 11.7. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 7 EULAR - moderate response.
[Analysis 11.8]
Analysis 11.8. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 8 EULAR - no response.
[Analysis 11.9]
Analysis 11.9. Comparison 11 Efficacy at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 9 DAS.
[Analysis 12.1]
Analysis 12.1. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
[Analysis 12.2]
Analysis 12.2. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
[Analysis 12.3]
Analysis 12.3. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
[Analysis 12.4]
Analysis 12.4. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Remission (DAS < 1.6).
[Analysis 12.5]
Analysis 12.5. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
[Analysis 12.6]
Analysis 12.6. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 6 Change in Total Sharp Score (from baseline).
[Analysis 12.7]
Analysis 12.7. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 7 Change in Erosion Score (from baseline).
[Analysis 12.8]
Analysis 12.8. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 12.9]
Analysis 12.9. Comparison 12 Efficacy at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
[Analysis 13.1]
Analysis 13.1. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
[Analysis 13.2]
Analysis 13.2. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
[Analysis 13.3]
Analysis 13.3. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
[Analysis 13.4]
Analysis 13.4. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Remission (DAS < 1.6).
[Analysis 13.5]
Analysis 13.5. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
[Analysis 13.6]
Analysis 13.6. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
[Analysis 13.7]
Analysis 13.7. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 7 Change in Erosion Score (from baseline).
[Analysis 13.8]
Analysis 13.8. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 13.9]
Analysis 13.9. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
[Analysis 13.10]
Analysis 13.10. Comparison 13 Efficacy at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 10 DAS.
[Analysis 14.1]
Analysis 14.1. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
[Analysis 14.2]
Analysis 14.2. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
[Analysis 14.3]
Analysis 14.3. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.
[Analysis 14.4]
Analysis 14.4. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Remission (DAS < 1.6).
[Analysis 14.5]
Analysis 14.5. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 5 Remission (DAS < 2.6).
[Analysis 14.6]
Analysis 14.6. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 6 Change in Total Sharp Score (TSS) (from baseline).
[Analysis 14.7]
Analysis 14.7. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 7 Change in Erosion Score (from baseline).
[Analysis 14.8]
Analysis 14.8. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 8 Change in Joint Space Narrowing Score (from baseline).
[Analysis 14.9]
Analysis 14.9. Comparison 14 Efficacy at three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 9 No progression of joint damage (TSS ≤ 0.5).
[Analysis 15.1]
Analysis 15.1. Comparison 15 Efficacy at six months: etanercept vs. placebo, Outcome 1 ACR20.
[Analysis 15.2]
Analysis 15.2. Comparison 15 Efficacy at six months: etanercept vs. placebo, Outcome 2 ACR50.
[Analysis 15.3]
Analysis 15.3. Comparison 15 Efficacy at six months: etanercept vs. placebo, Outcome 3 ACR70.
[Analysis 16.1]
Analysis 16.1. Comparison 16 Quality of life at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 HAQ: final value.
[Analysis 16.2]
Analysis 16.2. Comparison 16 Quality of life at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 EuroQoL VAS.
[Analysis 17.1]
Analysis 17.1. Comparison 17 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Satisfaction with treatment.
[Analysis 17.2]
Analysis 17.2. Comparison 17 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 HAQ score after treatment.
[Analysis 17.3]
Analysis 17.3. Comparison 17 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 EQ-5D VAS.
[Analysis 17.4]
Analysis 17.4. Comparison 17 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Reduction to normal health assessment (HAQ ≤ 0.5).
[Analysis 17.5]
Analysis 17.5. Comparison 17 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 5 Proportion stopping work.
[Analysis 17.6]
Analysis 17.6. Comparison 17 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 6 SF-36 Physical domain.
[Analysis 17.7]
Analysis 17.7. Comparison 17 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 7 SF-36 Mental domain.
[Analysis 18.1]
Analysis 18.1. Comparison 18 Quality of life at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Percentage improvement in HAQ (from baseline).
[Analysis 18.2]
Analysis 18.2. Comparison 18 Quality of life at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 HAQ score after treatment.
[Analysis 19.1]
Analysis 19.1. Comparison 19 Quality of life at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 HAQ score: final value.
[Analysis 19.2]
Analysis 19.2. Comparison 19 Quality of life at six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 EuroQoL VAS.
[Analysis 20.1]
Analysis 20.1. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 HAQ score after treatment.
[Analysis 20.2]
Analysis 20.2. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 HAQ score: change from baseline.
[Analysis 20.3]
Analysis 20.3. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Proportion of participants whose HAQ scores improved from baseline.
[Analysis 20.4]
Analysis 20.4. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 SF-36 score - physical domain: change from baseline.
[Analysis 20.5]
Analysis 20.5. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Proportion of participants whose SF-36 (physical) scores improved from baseline.
[Analysis 20.6]
Analysis 20.6. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 SF-36 score - mental domain: change from baseline.
[Analysis 20.7]
Analysis 20.7. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 Proportion of participants whose SF-36 (mental) scores improved from baseline.
[Analysis 20.8]
Analysis 20.8. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 8 ASHI: change from baseline.
[Analysis 20.9]
Analysis 20.9. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 9 Proportion of participants whose ASHI scores improved from baseline.
[Analysis 20.10]
Analysis 20.10. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 10 EQ-5D VAS.
[Analysis 20.11]
Analysis 20.11. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 11 Satisfaction with treatment.
[Analysis 20.12]
Analysis 20.12. Comparison 20 Quality of life at 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 12 Reduction to normal health assessment (HAQ ≤ 0.5).
[Analysis 21.1]
Analysis 21.1. Comparison 21 Quality of life at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Percentage improvement in HAQ (from baseline).
[Analysis 21.2]
Analysis 21.2. Comparison 21 Quality of life at two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 HAQ score after treatment.
[Analysis 22.1]
Analysis 22.1. Comparison 22 Quality of life at six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 HAQ score after treatment.
[Analysis 23.1]
Analysis 23.1. Comparison 23 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Satisfaction with treatment.
[Analysis 23.2]
Analysis 23.2. Comparison 23 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 HAQ score after treatment.
[Analysis 23.3]
Analysis 23.3. Comparison 23 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 EQ-5D VAS.
[Analysis 23.4]
Analysis 23.4. Comparison 23 Quality of life at 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Reduction to normal health assessment (HAQ ≤ 0.5).
[Analysis 24.1]
Analysis 24.1. Comparison 24 Quality of life at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Percentage improvement in HAQ (from baseline).
[Analysis 24.2]
Analysis 24.2. Comparison 24 Quality of life at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 HAQ score after treatment.
[Analysis 24.3]
Analysis 24.3. Comparison 24 Quality of life at two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 Satisfaction with treatment.
[Analysis 25.1]
Analysis 25.1. Comparison 25 Quality of life at six months: etanercept vs. placebo, Outcome 1 MOS: mental health (change from baseline).
[Analysis 25.2]
Analysis 25.2. Comparison 25 Quality of life at six months: etanercept vs. placebo, Outcome 2 MOS: energy/vitality (change from baseline).
[Analysis 26.1]
Analysis 26.1. Comparison 26 Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARDs, Outcome 1 Total.
[Analysis 26.2]
Analysis 26.2. Comparison 26 Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARDs, Outcome 2 Lack of efficacy.
[Analysis 26.3]
Analysis 26.3. Comparison 26 Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARDs, Outcome 3 Adverse event.
[Analysis 26.4]
Analysis 26.4. Comparison 26 Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARDs, Outcome 4 Death.
[Analysis 27.1]
Analysis 27.1. Comparison 27 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
[Analysis 27.2]
Analysis 27.2. Comparison 27 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 Lack of efficacy.
[Analysis 27.3]
Analysis 27.3. Comparison 27 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 Adverse events.
[Analysis 27.4]
Analysis 27.4. Comparison 27 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Death.
[Analysis 28.1]
Analysis 28.1. Comparison 28 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
[Analysis 28.2]
Analysis 28.2. Comparison 28 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 Lack of efficacy.
[Analysis 28.3]
Analysis 28.3. Comparison 28 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 Adverse event.
[Analysis 28.4]
Analysis 28.4. Comparison 28 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Death.
[Analysis 29.1]
Analysis 29.1. Comparison 29 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
[Analysis 29.2]
Analysis 29.2. Comparison 29 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 Lack of efficacy.
[Analysis 29.3]
Analysis 29.3. Comparison 29 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 Adverse event.
[Analysis 29.4]
Analysis 29.4. Comparison 29 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Death.
[Analysis 30.1]
Analysis 30.1. Comparison 30 Withdrawals six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Total.
[Analysis 30.2]
Analysis 30.2. Comparison 30 Withdrawals six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
[Analysis 30.3]
Analysis 30.3. Comparison 30 Withdrawals six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Adverse event.
[Analysis 31.1]
Analysis 31.1. Comparison 31 Withdrawals 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Total.
[Analysis 31.2]
Analysis 31.2. Comparison 31 Withdrawals 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
[Analysis 31.3]
Analysis 31.3. Comparison 31 Withdrawals 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Adverse event.
[Analysis 31.4]
Analysis 31.4. Comparison 31 Withdrawals 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Death.
[Analysis 32.1]
Analysis 32.1. Comparison 32 Withdrawals two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Total.
[Analysis 32.2]
Analysis 32.2. Comparison 32 Withdrawals two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
[Analysis 32.3]
Analysis 32.3. Comparison 32 Withdrawals two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Adverse event.
[Analysis 32.4]
Analysis 32.4. Comparison 32 Withdrawals two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Death.
[Analysis 33.1]
Analysis 33.1. Comparison 33 Withdrawals three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Total.
[Analysis 33.2]
Analysis 33.2. Comparison 33 Withdrawals three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 Lack of efficacy.
[Analysis 33.3]
Analysis 33.3. Comparison 33 Withdrawals three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Adverse event.
[Analysis 33.4]
Analysis 33.4. Comparison 33 Withdrawals three years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Death.
[Analysis 34.1]
Analysis 34.1. Comparison 34 Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
[Analysis 34.2]
Analysis 34.2. Comparison 34 Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
[Analysis 34.3]
Analysis 34.3. Comparison 34 Withdrawals six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
[Analysis 35.1]
Analysis 35.1. Comparison 35 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
[Analysis 35.2]
Analysis 35.2. Comparison 35 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
[Analysis 35.3]
Analysis 35.3. Comparison 35 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
[Analysis 35.4]
Analysis 35.4. Comparison 35 Withdrawals 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Deaths.
[Analysis 36.1]
Analysis 36.1. Comparison 36 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
[Analysis 36.2]
Analysis 36.2. Comparison 36 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
[Analysis 36.3]
Analysis 36.3. Comparison 36 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
[Analysis 36.4]
Analysis 36.4. Comparison 36 Withdrawals two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Deaths.
[Analysis 37.1]
Analysis 37.1. Comparison 37 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
[Analysis 37.2]
Analysis 37.2. Comparison 37 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 Lack of efficacy.
[Analysis 37.3]
Analysis 37.3. Comparison 37 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 Adverse events.
[Analysis 37.4]
Analysis 37.4. Comparison 37 Withdrawals three years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Deaths.
[Analysis 38.1]
Analysis 38.1. Comparison 38 Withdrawals six months: etanercept vs. placebo, Outcome 1 Total.
[Analysis 38.2]
Analysis 38.2. Comparison 38 Withdrawals six months: etanercept vs. placebo, Outcome 2 Lack of efficacy.
[Analysis 38.3]
Analysis 38.3. Comparison 38 Withdrawals six months: etanercept vs. placebo, Outcome 3 Adverse event.
[Analysis 39.1]
Analysis 39.1. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
[Analysis 39.2]
Analysis 39.2. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 Abdominal pain.
[Analysis 39.3]
Analysis 39.3. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 Asthenia.
[Analysis 39.4]
Analysis 39.4. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Bone pain/arthralgia.
[Analysis 39.5]
Analysis 39.5. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 5 Bronchitis.
[Analysis 39.6]
Analysis 39.6. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 6 Diarrhoea.
[Analysis 39.7]
Analysis 39.7. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 7 Dizziness.
[Analysis 39.8]
Analysis 39.8. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 8 Dyspepsia.
[Analysis 39.9]
Analysis 39.9. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 9 Fever.
[Analysis 39.10]
Analysis 39.10. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 10 Flu syndrome.
[Analysis 39.11]
Analysis 39.11. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 11 Headache.
[Analysis 39.12]
Analysis 39.12. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 12 Hypertension.
[Analysis 39.13]
Analysis 39.13. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 13 Increased cough.
[Analysis 39.14]
Analysis 39.14. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 14 Infection.
[Analysis 39.15]
Analysis 39.15. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 15 Injection site reaction.
[Analysis 39.16]
Analysis 39.16. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 16 Injection site haemorrhage.
[Analysis 39.17]
Analysis 39.17. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 17 Leukopenia.
[Analysis 39.18]
Analysis 39.18. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 18 Miscellaneous skin infections.
[Analysis 39.19]
Analysis 39.19. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 19 Mouth ulcers.
[Analysis 39.20]
Analysis 39.20. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 20 Nausea.
[Analysis 39.21]
Analysis 39.21. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 21 Pain.
[Analysis 39.22]
Analysis 39.22. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 22 Paraesthesia.
[Analysis 39.23]
Analysis 39.23. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 23 Pharyngitis (non-infectious).
[Analysis 39.24]
Analysis 39.24. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 24 Pharyngitis or laryngitis.
[Analysis 39.25]
Analysis 39.25. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 25 Pruritus.
[Analysis 39.26]
Analysis 39.26. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 26 Rash.
[Analysis 39.27]
Analysis 39.27. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 27 Rhinitis.
[Analysis 39.28]
Analysis 39.28. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 28 Trauma/accidental injury.
[Analysis 39.29]
Analysis 39.29. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 29 Upper respiratory tract infection.
[Analysis 39.30]
Analysis 39.30. Comparison 39 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 30 Vomiting.
[Analysis 40.1]
Analysis 40.1. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Nausea.
[Analysis 40.2]
Analysis 40.2. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 Nasopharyngitis.
[Analysis 40.3]
Analysis 40.3. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 Serious infections.
[Analysis 40.4]
Analysis 40.4. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Worsening of rheumatoid arthritis.
[Analysis 40.5]
Analysis 40.5. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 5 Breast cancer.
[Analysis 40.6]
Analysis 40.6. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 6 Chest pain.
[Analysis 40.7]
Analysis 40.7. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 7 Pneumonia.
[Analysis 40.8]
Analysis 40.8. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 8 Cholelithiasis.
[Analysis 40.9]
Analysis 40.9. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 9 Invertebral disc protrusion.
[Analysis 40.10]
Analysis 40.10. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 10 Osteoarthritis.
[Analysis 40.11]
Analysis 40.11. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 11 Interstitial lung disease.
[Analysis 40.12]
Analysis 40.12. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 12 Hip arthroplasty.
[Analysis 40.13]
Analysis 40.13. Comparison 40 Adverse events within 12 months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 13 Malignancy.
[Analysis 41.1]
Analysis 41.1. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 Total.
[Analysis 41.2]
Analysis 41.2. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 Accidental injury.
[Analysis 41.3]
Analysis 41.3. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 Abdominal pain.
[Analysis 41.4]
Analysis 41.4. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 4 Asthenia.
[Analysis 41.5]
Analysis 41.5. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 5 Arthralgia.
[Analysis 41.6]
Analysis 41.6. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 6 Back pain.
[Analysis 41.7]
Analysis 41.7. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 7 Bronchitis.
[Analysis 41.8]
Analysis 41.8. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 8 Diarrhoea.
[Analysis 41.9]
Analysis 41.9. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 9 Dyspepsia.
[Analysis 41.10]
Analysis 41.10. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 10 Flu syndrome.
[Analysis 41.11]
Analysis 41.11. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 11 Gingival/dental infection.
[Analysis 41.12]
Analysis 41.12. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 12 Headache.
[Analysis 41.13]
Analysis 41.13. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 13 Hypertension.
[Analysis 41.14]
Analysis 41.14. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 14 Increase in cough.
[Analysis 41.15]
Analysis 41.15. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 15 Infections (total).
[Analysis 41.16]
Analysis 41.16. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 16 Injection site haemorrhage.
[Analysis 41.17]
Analysis 41.17. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 17 Injection Site Reaction.
[Analysis 41.18]
Analysis 41.18. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 18 Malignancy.
[Analysis 41.19]
Analysis 41.19. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 19 Miscellaneous skin infections.
[Analysis 41.20]
Analysis 41.20. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 20 Nausea.
[Analysis 41.21]
Analysis 41.21. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 21 Pain.
[Analysis 41.22]
Analysis 41.22. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 22 Paraesthesia.
[Analysis 41.23]
Analysis 41.23. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 23 Pharyngitis or laryngitis.
[Analysis 41.24]
Analysis 41.24. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 24 Rash.
[Analysis 41.25]
Analysis 41.25. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 25 Serious infections.
[Analysis 41.26]
Analysis 41.26. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 26 Sinusitis.
[Analysis 41.27]
Analysis 41.27. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 27 Upper respiratory tract infection.
[Analysis 41.28]
Analysis 41.28. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 28 Vomiting.
[Analysis 41.29]
Analysis 41.29. Comparison 41 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 29 Worsening of rheumatoid arthritis.
[Analysis 42.1]
Analysis 42.1. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Total.
[Analysis 42.2]
Analysis 42.2. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 Alopecia.
[Analysis 42.3]
Analysis 42.3. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Accidental injury.
[Analysis 42.4]
Analysis 42.4. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Asthenia.
[Analysis 42.5]
Analysis 42.5. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Arthralgia.
[Analysis 42.6]
Analysis 42.6. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 Bronchitis.
[Analysis 42.7]
Analysis 42.7. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 Chest discomfort.
[Analysis 42.8]
Analysis 42.8. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 8 Dyspepsia.
[Analysis 42.9]
Analysis 42.9. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 9 Dizziness.
[Analysis 42.10]
Analysis 42.10. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 10 Oedema.
[Analysis 42.11]
Analysis 42.11. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 11 Elevation in alanine transaminase.
[Analysis 42.12]
Analysis 42.12. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 12 Enlargement of lymph nodes.
[Analysis 42.13]
Analysis 42.13. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 13 Fever.
[Analysis 42.14]
Analysis 42.14. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 14 Gastrointestinal symptoms/abdominal pain.
[Analysis 42.15]
Analysis 42.15. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 15 Headache.
[Analysis 42.16]
Analysis 42.16. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 16 Increased blood pressure.
[Analysis 42.17]
Analysis 42.17. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 17 Increased cough.
[Analysis 42.18]
Analysis 42.18. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 18 Infection at another site/pharyngitis or laryngitis, flu syndrome or miscellaneous skin infections.
[Analysis 42.19]
Analysis 42.19. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 19 Injection site haemorrhage.
[Analysis 42.20]
Analysis 42.20. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 20 Injection site reaction.
[Analysis 42.21]
Analysis 42.21. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 21 Insomnia.
[Analysis 42.22]
Analysis 42.22. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 22 Leukopenia.
[Analysis 42.23]
Analysis 42.23. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 23 Nausea.
[Analysis 42.24]
Analysis 42.24. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 24 Pain.
[Analysis 42.25]
Analysis 42.25. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 25 Paraesthesia.
[Analysis 42.26]
Analysis 42.26. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 26 Pharyngitis (non-infectious).
[Analysis 42.27]
Analysis 42.27. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 27 Pruritus.
[Analysis 42.28]
Analysis 42.28. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 28 Rhinitis.
[Analysis 42.29]
Analysis 42.29. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 29 Skin rash.
[Analysis 42.30]
Analysis 42.30. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 30 Total infectious adverse events.
[Analysis 42.31]
Analysis 42.31. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 31 Upper respiratory tract infection.
[Analysis 42.32]
Analysis 42.32. Comparison 42 Adverse events within six months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 32 Vision disorder.
[Analysis 43.1]
Analysis 43.1. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Alopecia.
[Analysis 43.2]
Analysis 43.2. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 Abdominal pain.
[Analysis 43.3]
Analysis 43.3. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Asthenia.
[Analysis 43.4]
Analysis 43.4. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Back pain.
[Analysis 43.5]
Analysis 43.5. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Diarrhoea.
[Analysis 43.6]
Analysis 43.6. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 Dizziness.
[Analysis 43.7]
Analysis 43.7. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 Dyspepsia.
[Analysis 43.8]
Analysis 43.8. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 8 Ecchymosis.
[Analysis 43.9]
Analysis 43.9. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 9 Headache.
[Analysis 43.10]
Analysis 43.10. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 10 Influenza-like syndrome.
[Analysis 43.11]
Analysis 43.11. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 11 Injection site haemorrhagia.
[Analysis 43.12]
Analysis 43.12. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 12 Injection site reaction.
[Analysis 43.13]
Analysis 43.13. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 13 Mouth ulcers.
[Analysis 43.14]
Analysis 43.14. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 14 Nausea.
[Analysis 43.15]
Analysis 43.15. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 15 Rash.
[Analysis 43.16]
Analysis 43.16. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 16 Rhinitis.
[Analysis 43.17]
Analysis 43.17. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 17 Sinusitis.
[Analysis 43.18]
Analysis 43.18. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 18 Skin infection.
[Analysis 43.19]
Analysis 43.19. Comparison 43 Adverse events within 12 months: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 19 Upper respiratory tract infection.
[Analysis 44.1]
Analysis 44.1. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 Total.
[Analysis 44.2]
Analysis 44.2. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 Abdominal pain.
[Analysis 44.3]
Analysis 44.3. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 Asthenia.
[Analysis 44.4]
Analysis 44.4. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 4 Accidental injury.
[Analysis 44.5]
Analysis 44.5. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 5 Arthralgia.
[Analysis 44.6]
Analysis 44.6. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 6 Back pain.
[Analysis 44.7]
Analysis 44.7. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 7 Bronchitis.
[Analysis 44.8]
Analysis 44.8. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 8 Diarrhoea.
[Analysis 44.9]
Analysis 44.9. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 9 Dyspepsia.
[Analysis 44.10]
Analysis 44.10. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 10 Flu syndrome.
[Analysis 44.11]
Analysis 44.11. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 11 Gingival/dental infection.
[Analysis 44.12]
Analysis 44.12. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 12 Headache.
[Analysis 44.13]
Analysis 44.13. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 13 Hypertension.
[Analysis 44.14]
Analysis 44.14. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 14 Increased cough.
[Analysis 44.15]
Analysis 44.15. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 15 Infections (total).
[Analysis 44.16]
Analysis 44.16. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 16 Injection site haemorrhage.
[Analysis 44.17]
Analysis 44.17. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 17 Injection site reaction.
[Analysis 44.18]
Analysis 44.18. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 18 Malignancy.
[Analysis 44.19]
Analysis 44.19. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 19 Miscellaneous skin infections.
[Analysis 44.20]
Analysis 44.20. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 20 Nausea.
[Analysis 44.21]
Analysis 44.21. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 21 Pain.
[Analysis 44.22]
Analysis 44.22. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 22 Paraesthesia.
[Analysis 44.23]
Analysis 44.23. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 23 Pharyngitis or laryngitis.
[Analysis 44.24]
Analysis 44.24. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 24 Rash.
[Analysis 44.25]
Analysis 44.25. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 25 Rheumatoid arthritis.
[Analysis 44.26]
Analysis 44.26. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 26 Serious infections.
[Analysis 44.27]
Analysis 44.27. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 27 Sinusitis.
[Analysis 44.28]
Analysis 44.28. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 28 Upper respiratory tract infection.
[Analysis 44.29]
Analysis 44.29. Comparison 44 Adverse events within two years: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 29 Vomiting.
[Analysis 45.1]
Analysis 45.1. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
[Analysis 45.2]
Analysis 45.2. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 Asthenia.
[Analysis 45.3]
Analysis 45.3. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 Blood and lymphatic system disorders/leukopenia.
[Analysis 45.4]
Analysis 45.4. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Dizziness.
[Analysis 45.5]
Analysis 45.5. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 5 Fever.
[Analysis 45.6]
Analysis 45.6. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 6 Flu syndrome.
[Analysis 45.7]
Analysis 45.7. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 7 Gastrointestinal symptoms/abdominal pain/dyspepsia.
[Analysis 45.8]
Analysis 45.8. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 8 Headache.
[Analysis 45.9]
Analysis 45.9. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 9 Hepatobiliary disorders.
[Analysis 45.10]
Analysis 45.10. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 10 Hypertension.
[Analysis 45.11]
Analysis 45.11. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 11 Increased cough.
[Analysis 45.12]
Analysis 45.12. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 12 Infection and infestations/total infectious adverse events.
[Analysis 45.13]
Analysis 45.13. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 13 Injection site reaction/injection site haemorrhage/general disorders and administration site conditions.
[Analysis 45.14]
Analysis 45.14. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 14 Injury, poisoning and procedural complications/accidental Injury.
[Analysis 45.15]
Analysis 45.15. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 15 Malignancy.
[Analysis 45.16]
Analysis 45.16. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 16 Metabolism and nutrition disorders.
[Analysis 45.17]
Analysis 45.17. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 17 Miscellaneous skin infections.
[Analysis 45.18]
Analysis 45.18. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 18 Musculoskeletal and connective tissue disorders/arthralgia.
[Analysis 45.19]
Analysis 45.19. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 19 Nausea.
[Analysis 45.20]
Analysis 45.20. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 20 Nervous system disorders/paraesthesia.
[Analysis 45.21]
Analysis 45.21. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 21 Pain.
[Analysis 45.22]
Analysis 45.22. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 22 Pharyngitis (non-infectious).
[Analysis 45.23]
Analysis 45.23. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 23 Pharyngitis or laryngitis (infectious).
[Analysis 45.24]
Analysis 45.24. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 24 Reproductive system and breast disorders.
[Analysis 45.25]
Analysis 45.25. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 25 Respiratory, thoracic and mediastinal disorders/bronchitis.
[Analysis 45.26]
Analysis 45.26. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 26 Rhinitis.
[Analysis 45.27]
Analysis 45.27. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 27 Skin and subcutaneous tissue disorders/rash/pruritus.
[Analysis 45.28]
Analysis 45.28. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 28 Total serious adverse events.
[Analysis 45.29]
Analysis 45.29. Comparison 45 Adverse events within six months: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 29 Upper respiratory tract infection.
[Analysis 46.1]
Analysis 46.1. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 Total.
[Analysis 46.2]
Analysis 46.2. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 Abdominal pain.
[Analysis 46.3]
Analysis 46.3. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 Accidental injury.
[Analysis 46.4]
Analysis 46.4. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 4 Arthralgia.
[Analysis 46.5]
Analysis 46.5. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 5 Asthenia.
[Analysis 46.6]
Analysis 46.6. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 6 Back pain.
[Analysis 46.7]
Analysis 46.7. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 7 Bronchitis.
[Analysis 46.8]
Analysis 46.8. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 8 Diarrhoea.
[Analysis 46.9]
Analysis 46.9. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 9 Dyspepsia.
[Analysis 46.10]
Analysis 46.10. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 10 Flu syndrome.
[Analysis 46.11]
Analysis 46.11. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 11 Gingival/dental infection.
[Analysis 46.12]
Analysis 46.12. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 12 Headache.
[Analysis 46.13]
Analysis 46.13. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 13 Hypertension.
[Analysis 46.14]
Analysis 46.14. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 14 Increased cough.
[Analysis 46.15]
Analysis 46.15. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 15 Infections (total).
[Analysis 46.16]
Analysis 46.16. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 16 Injection site haemorrhage.
[Analysis 46.17]
Analysis 46.17. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 17 Injection site reaction.
[Analysis 46.18]
Analysis 46.18. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 18 Malignancy.
[Analysis 46.19]
Analysis 46.19. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 19 Miscellaneous skin infections.
[Analysis 46.20]
Analysis 46.20. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 20 Nausea.
[Analysis 46.21]
Analysis 46.21. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 21 Pain.
[Analysis 46.22]
Analysis 46.22. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 22 Paraesthesia.
[Analysis 46.23]
Analysis 46.23. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 23 Pharyngitis or laryngitis.
[Analysis 46.24]
Analysis 46.24. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 24 Rash.
[Analysis 46.25]
Analysis 46.25. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 25 Rheumatoid arthritis.
[Analysis 46.26]
Analysis 46.26. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 26 Serious infections.
[Analysis 46.27]
Analysis 46.27. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 27 Sinusitis.
[Analysis 46.28]
Analysis 46.28. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 28 Upper respiratory tract infection.
[Analysis 46.29]
Analysis 46.29. Comparison 46 Adverse events within two years: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 29 Vomiting.
[Analysis 47.1]
Analysis 47.1. Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 1 Diarrhoea.
[Analysis 47.2]
Analysis 47.2. Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 2 Headache.
[Analysis 47.3]
Analysis 47.3. Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 3 Injection site reaction.
[Analysis 47.4]
Analysis 47.4. Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 4 Rhinitis.
[Analysis 47.5]
Analysis 47.5. Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 5 Sinusitis.
[Analysis 47.6]
Analysis 47.6. Comparison 47 Adverse events within six months: etanercept vs. placebo, Outcome 6 Upper respiratory tract infection.
[Analysis 48.1]
Analysis 48.1. Comparison 48 Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 1 ACR20.
[Analysis 48.2]
Analysis 48.2. Comparison 48 Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 2 ACR50.
[Analysis 48.3]
Analysis 48.3. Comparison 48 Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. DMARD, Outcome 3 ACR70.
[Analysis 49.1]
Analysis 49.1. Comparison 49 Sensitivity analysis: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 1 ACR20.
[Analysis 49.2]
Analysis 49.2. Comparison 49 Sensitivity analysis: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 2 ACR50.
[Analysis 49.3]
Analysis 49.3. Comparison 49 Sensitivity analysis: etanercept vs. disease-modifying anti-rheumatic drug (DMARD), Outcome 3 ACR-70.
[Analysis 50.1]
Analysis 50.1. Comparison 50 Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 1 ACR20.
[Analysis 50.2]
Analysis 50.2. Comparison 50 Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 2 ACR50.
[Analysis 50.3]
Analysis 50.3. Comparison 50 Sensitivity analysis: etanercept + disease-modifying anti-rheumatic drug (DMARD) vs. etanercept, Outcome 3 ACR70.